Sleep Disruption in Menopause: No Approved Therapy Exists for the Most Common Complaint
A review in Menopause reveals that despite affecting 40-56% of peri- and postmenopausal women, sleep disturbance associated with menopause has no specifically approved pharmacological treatment.
Read the original article at MenopauseKairos™'s Take
Kairos™'s perspective on this story
Published in the journal Menopause in August 2024, this review by Pauline Maki, Nick Panay, and James Simon confronts a striking gap in menopausal medicine: between 40% and 56% of peri- and postmenopausal women report significant sleep difficulties, yet there are currently no therapies specifically approved for sleep disturbance associated with menopause. The review details the characteristic pattern — frequent nighttime awakenings and increased time spent awake after sleep onset — and traces its mechanisms to declining estrogen levels, fluctuations in follicle-stimulating hormone, and the dysregulation of hypothalamic kisspeptin/neurokinin B/dynorphin neurons that link reproductive hormone pathways to thermoregulation and the circadian sleep-wake cycle.
The clinical picture is compounded by a bidirectional relationship between vasomotor symptoms and sleep: nighttime hot flashes and sweats fragment sleep, while poor sleep amplifies next-day vasomotor severity. Beyond night sweats, hormonal changes directly affect sleep architecture independently of temperature dysregulation. The review notes that sleep disturbance during menopause has wide-ranging consequences — affecting mood, cognitive function, work performance, personal relationships, and long-term cardiometabolic health. Despite this, many women and clinicians treat menopause-related sleep problems with generic insomnia approaches rather than addressing the hormonal and thermoregulatory drivers specific to this population.
Why This Matters
Sleep is not a standalone symptom during menopause — it is a force multiplier that amplifies or attenuates nearly every other aspect of the transition. Poor sleep worsens cognitive fog, mood instability, pain perception, and metabolic function. Yet without tracking, sleep disruption is reported as "I'm not sleeping well" — a description that does not distinguish between difficulty falling asleep, frequent awakenings, early morning waking, or hot-flash-driven disruption. Each pattern points to a different intervention. A monitoring platform that captures sleep quality, wake episodes, night sweat occurrences, and next-day function creates a dataset that reveals the specific pattern and helps clinicians target the cause, not just the symptom.
Ready to start tracking?
Kairos™ tracks, scores, and interprets the symptoms of midlife hormonal change — for both women and men.
Get StartedMore from the newsroom
England Adds Menopause to Routine NHS Health Checks for Nearly 5 Million Women
The UK government announced that menopause will be integrated into routine NHS health checks for women aged 40 to 74 — the first time the national health system has systematically screened for menopause symptoms.
Only 8% of Symptomatic Women Receive a Perimenopause or Menopause Diagnosis
A large-scale analysis finds that more than half of women aged 40-64 experience perimenopause or menopause symptoms, yet only 8% receive a confirmed diagnosis — exposing a systemic recognition gap in clinical care.
The WHI at 30: How One Trial Reshaped Hormone Therapy for a Generation
A comprehensive JAMA review revisits the Women's Health Initiative 30 years after launch, clarifying what the landmark trial actually found and what it means for clinical practice today.